The study was presented at the ‘Deutscher Anesthesie Kongress 2002’ in Nuernberg, 22–25 June 2002.
Pretreatment with sufentanil reduces myoclonus after etomidate
Article first published online: 10 APR 2003
Acta Anaesthesiologica Scandinavica
Volume 47, Issue 4, pages 482–484, April 2003
How to Cite
Hueter, L., Schwarzkopf, K., Simon, M., Bredle, D. and Fritz, H. (2003), Pretreatment with sufentanil reduces myoclonus after etomidate. Acta Anaesthesiologica Scandinavica, 47: 482–484. doi: 10.1034/j.1399-6576.2003.00081.x
- Issue published online: 10 APR 2003
- Article first published online: 10 APR 2003
- Accepted for publication 21 November 2002
- adverse effects;
Background: Myoclonic movements are a common problem during the induction of general anesthesia with etomidate. We investigated the influence of pretreatment with the opioid sufentanil on the incidence of etomidate-induced myoclonus.
Methods: Forty female patients (ASA physical status I–III) were randomly assigned to receive double-blinded either 0.3 µg kg−1 of sufentanil or placebo 150 s before the induction of sleep with 0.3 mg kg−1 of etomidate. The patients were observed for any myoclonic movement. Grade of dizziness, breathing frequency, non-invasive blood pressure and heart rate were measured during the study period.
Results: None of the 20 patients receiving sufentanil had myoclonic movements after the administration of etomidate, whereas 16 patients in the placebo group (80%) experienced such movements (P<0.01). No cases of apnoea before induction of sleep were seen in the sufentanil group.
Conclusion: Sufentanil 0.3 µg kg−1 is an effective and safe drug to reduce myoclonus after etomidate without causing any harmful side-effect.